Receive our newsletter – data, insights and analysis delivered to you
  1. Uncategorized
  2. c-icon icon-chevron-right
June 2, 2020

‘Social responsibility’ may be reason chloroquine trials are continuing despite setbacks

By Jamie Bell

Social responsibility may be a key reason why researchers are still conducting trials for chloroquine as a Covid-19 treatment despite recent setbacks, says an analyst.

Last month, an international group of researchers began clinical trials to investigate whether the anti-malaria drug could prevent the novel coronavirus, or reduce its severity in front-line healthcare workers.

And this trial looks set to continue — even though the WHO (World Health Organisation) announced on May 25 it was temporarily dropping hydroxychloroquine from its global study of potential Covid-19 treatments due to safety concerns.

Read the full article here.

Related Companies

Content from our partners
Africa’s last mile: Building viable vaccine supply chains
Why this global life sciences COO believes relocation to Charleston, SC, was key to achieving next-level success
Patient-centric pharma logistics: How CRYOPDP delivers hope worldwide

Topics in this article:
NEWSLETTER Sign up Tick the boxes of the newsletters you would like to receive. Key drug pipeline and competitive landscape changes based on the latest clinical activity, sent every Tuesday. Curated analysis and data-driven insights on clinical trials strategy and operations, sent every Thursday. The pharmaceutical industry's most comprehensive news and information delivered every month.
I consent to GlobalData UK Limited collecting my details provided via this form in accordance with the Privacy Policy
SUBSCRIBED

THANK YOU